Login to Your Account

Avanir migraine CRL no investor surprise

By Randy Osborne
Staff Writer

Monday, December 1, 2014

As expected, the FDA hit Avanir Pharmaceuticals Inc. late Wednesday with a complete response letter related to the NDA for AVP-825 for the acute treatment of migraine.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription